Biogen Reports Q3 2026 Results: Total Revenue Up 11% to $2.8B and Raises FY Guidance Floor
BIOGEN INC.
Subscribe to track BIIB
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Biogen Inc. ($BIIB) filed an 8-K reporting Q3 2026 financial results under Item 2.02. Total revenue increased 11% YoY to $2.804B, driven by a 49% growth in its Growth Portfolio ($1.26B). GAAP EPS was $(0.14) due to acquisition-related charges, while Non-GAAP diluted EPS reached $2.62 (including $284M in acquired IPR&D and milestones). The company raised the lower end of its FY 2026 Non-GAAP diluted EPS guidance range to $12.20–$13.00 (from $12.00–$13.00).
Comprehensive Analysis
Executive Summary
On October 28, 2026, Biogen Inc. filed a Current Report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), announcing financial results for the third quarter ended September 30, 2026.
Key Financial Highlights
- Total Revenue: $2,804 million in Q3 2026, an increase of 11% year-over-year (10% at constant currency) compared to $2,535 million in Q3 2025.
- Growth Portfolio Revenue: Reached $1.26 billion, up 49% year-over-year, accounting for 63% of Core Pharmaceutical revenue.
- GAAP Diluted EPS: $(0.14), impacted by transaction-related charges, down from $3.17 in Q3 2025.
- Non-GAAP Diluted EPS: $2.62, compared to $4.81 in Q3 2025, reflecting $284 million ($0.XX per share impact) in acquired IPR&D, upfront, and milestone expenses primarily linked to the RayThera Inc. acquisition.
Key Product Performance
- SPINRAZA: $461 million (+23% YoY), driven by accelerated conversion to the high-dose regimen.
- LEQEMBI: Global in-market sales recorded by Eisai reached $202 million (+67% YoY; U.S. in-market sales of $107 million).
- SYFOVRE: $191 million (+27% YoY), showing strong volume growth following the Apellis acquisition.
- SKYCLARYS: $178 million (+34% YoY).
- VUMERITY: $192 million (-11% YoY), impacted by U.S. formulary dynamics.
- Total MS Product Revenue: $919 million, down 13% YoY due to ongoing legacy franchise erosion.
FY 2026 Guidance Update
Biogen raised the lower bound of its full-year 2026 Non-GAAP diluted EPS guidance range to $12.20 to $13.00 (previously $12.00 to $13.00), citing operational momentum and favorability regarding Apellis dilution.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.